Compare
Mresvia vs. Arexvy

MRESVIA is an mRNA vaccine that's used to protect adults 60 years and older from illness caused by respiratory syncytial virus (RSV). This vaccine is injected into the muscle by a trained healthcare professional (HCP), and you only need to get one dose. Some potential side effects of the MRESVIA RSV vaccine include pain at the injection site, tiredness, headache, and muscle pain.

• Prevention of illness caused by respiratory syncytial virus (RSV)

• Pain at the injection site (56%)
• Feeling tired (31%)
• Headache (27%)
• Muscle pain (26%)
• Joint pain (22%)
• Underarm swelling or tenderness (15%)
• Chills (12%)

• Severe allergic reaction
• Fainting
• Vaccine might not work as well for people with a weakened immune system

Arexvy (RSV vaccine) is the first FDA-approved vaccine to help lower your risk of getting serious lung infections caused by respiratory syncytial virus (RSV). You can get it if you're age 60 or older, and in some cases starting at age 18 if you have a higher risk of severe illness from RSV. Arexvy (RSV vaccine) is given once as a single injection into the muscle. Common side effects include tiredness, muscle pain, and injection site reactions like pain, swelling, or redness.

Prevention of serious lung infections caused by respiratory syncytial virus (RSV) in:

• Adults 60 years and older
• Adults 18 to 59 years old who have a higher risk of illness due to RSV

18 to 49 years old:

• Pain at the injection site (76%)
• Muscle pain (60%)
• Tiredness (60%)
• Headache (44%)
• Joint pain (28%)

50 to 59 years old:

• Pain at the injection site (76%)
• Tiredness (40%)
• Muscle pain (36%)
• Headache (32%)
• Joint pain (23%)

60 years and older:

• Pain at the injection site (61%)
• Tiredness (34%)
• Muscle pain (29%)
• Headache (27%)
• Joint pain (18%)

• Guillain-Barré syndrome
• Severe allergic reaction
• Fainting
• Weaker vaccine protection